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STATE-OF-THE-ART PAPERISTATE-OF-THE-ART PAPER197Neurological and Cardiac Benefits of Therapeutic HypothermiaCédric Delhaye, Michael Mahmoudi, Ron Waksman
Delhaye and associates provide a brief review of hypothermia therapy (HT), the clinical
evidence for its benefit, different cooling techniques, and potential adverse effects associated
with HT. Randomized studies have shown that HT for 12 to 24 h decreases mortality and
improves neurological outcomes in unconscious adult patients with spontaneous circulation
after out-of-hospital cardiac arrest due to ventricular fibrillation (VF). Observational studies
support its early application in patients with non-VF cardiac arrest and in post-resuscitation
circulatory shock. In patients with acute myocardial infarction, some studies have suggested
benefit in large anterior infarctions, but the available clinical evidence does not yet support
HT as the standard of care.CLINICAL RESEARCH INTERVENTIONAL CARDIOLOGY
211ncidence and Predictors of Paravalvular Leakage
and Transvalvular Regurgitation After TAVIAxel Unbehaun, Miralem Pasic, Stephan Dreysse, Thorsten Drews, Marian Kukucka,
Alexander Mladenow, Ekaterina Ivanitskaja-Kühn, Roland Hetzer, Semih Buz
Unbehaun and colleagues review their results with 358 patients who underwent transapical
transcatheter aortic valve implantation (TAVI) using their modified procedural strategy which
consists of precise positioning of the prosthesis and immediate additional treatment to
eliminate paravalvular leakage. Balloon re-dilatation of the transcatheter valve was performed
in 5% of patients, and an additional, second valve was implanted in 4% to address
paravalvular regurgitation. At the end of the procedure, one-half of patients had no
paravalvular or transvalvular regurgitation, and only 0.6% had moderate leakage. This
modified procedural strategy of transapical TAVI produces low rates prosthetic regurgitation.(continued on page A-26)
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(HEART FAILURE222Elevated PA Pressures Associated With Higher Mortality in Patients With HFFrancesca Bursi, Sheila M. McNallan, Margaret M. Redfield, Vuyisile T. Nkomo, Carolyn S. P. Lam,
Susan A. Weston, Ruoxiang Jiang, Véronique L. Roger
Bursi and colleagues measured pulmonary artery systolic pressure (PASP) as part of a
standard echocardiogram in patients diagnosed with heart failure (HF). Olmsted County
residents with HF prospectively underwent assessment of ejection fraction (EF), diastolic
function, and PASP by Doppler echocardiography. The results showed a strong, positive,
graded association between PASP and subsequent mortality, that was independent of age, sex,
comorbidities, EF, and diastolic function. PASP strongly predicts the medium-term risk of
death in patients with HF.Editorial Comment: Myung H. Park, Mandeep R. Mehra, p. 232VALVULAR HEART DISEASE235Outcomes in Asymptomatic Patients With AS Depend on Flow and GradientPatrizio Lancellotti, Julien Magne, Erwan Donal, Laurent Davin, Kim O’Connor, Monica Rosca,
Catherine Szymanski, Bernard Cosyns, Luc A. Piérard
Lancellotti and colleagues studied the clinical course of patients with asymptomatic severe
aortic stenosis (AS) according to a new proposed AS grading classification which incorporates
flow and gradient measurements. Transthoracic echocardiography was performed in 150
consecutive patients with asymptomatic severe AS (aortic valve area 1.0 cm) and normal
xercise test. Patients were classified in 4 groups depending on left ventricular flow state
normal flow vs. low flow: 35 ml/m2) and pressure gradient levels (low gradient [LG] vs. high
gradient [HG]: 40 mm Hg). At 2 years, cardiac event-free survival at 83% was significantly
higher in normal flow/LG patients compared to the other groups. Patients with LF/LG were
5 times more likely to suffer a cardiac event compared to those with LF/HG. The use of an
AS grading classification integrating flow and gradient patterns allows a better prediction of
the clinical outcome of patients with asymptomatic severe AS.
Editorial Comment: Frank A. Flachskampf, Mohammad Kavianipour, p. 244(continued on page A-27)
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Antje Elger, Omar Maarouf, David Antonio Sola-Del Valle, Matthew O’Rourke, Evan Sherman, Peter Lee,
Abdallah Geara, Philip Imus, Achuta Guddati, Allison Polland, Wasiq Rahman, Saban Elitok,
Nasir Malik, James Giglio, Suzanne El-Sayegh, Prasad Devarajan, Sudarshan Hebbar, Subodh J. Saggi,
Barry Hahn, Ralph Kettritz, Friedrich C. Luft, Jonathan Barasch
Nickolas and colleagues performed a multicenter study to determine the diagnostic and
prognostic value of urinary biomarkers of intrinsic acute kidney injury (AKI). Five urinary
biomarkers (neutrophil gelatinase-associated lipocalin, [uNGAL]; kidney injury molecule-1
[uKIM-1]; liver-type fatty acid binding protein [uL-FABP]; interleukin-18 [uIL-18]; and
cystatin C [uCysC]) were measured in 1,635 unselected patients at the time of hospital
admission. All biomarkers were elevated in intrinsic AKI, but uNGAL was most accurate
(specificity 81%, sensitivity 68%) and predictive of AKI severity. uNGAL and uKIM-1
predicted a composite outcome of dialysis initiation or death during hospitalization and these
biomarkers also identified a substantial subpopulation with low serum creatinine who were at
risk for adverse renal events. Urinary biomarkers of nephron damage enable prospective
diagnostic and prognostic stratification.PRE-CLINICAL RESEARCH PRE-CLINICAL RESEARCH256Intramyocardial Injection of Platelet Gel Promotes Endogenous Repair in Rat ModelKe Cheng, Konstantinos Malliaras, Deliang Shen, Eleni Tseliou, Vittoria Ionta, Jeremy Smith,
Giselle Galang, Baiming Sun, Christiane Houde, Eduardo Marba´n
Platelet gel (also known as platelet fibrin scaffold) is formed by mixing host plasma with cell
culture media containing a high concentration of free calcium resulting in gelation starting in
30 s and complete within 120 s. Cheng and colleagues explored the therapeutic potential of
platelet gel for the treatment of myocardial infarction in a rat model. After delivery into
infarcted rat hearts, the gel was efficiently infiltrated by cardiomyocytes and endothelial cells.
The cardiac function of control-injected animals deteriorated over the 6-week time course,
while that of platelet gel-injected animals did not. The striking functional benefits, the
simplicity of manufacturing, and the potentially autologous nature of this biomaterial merit
further research.(continued on page A-28)
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265FS Improves Endothelial Function and
Reduces Atherosclerotic Lesion Formation in MiceJunichi Matsubara, Seigo Sugiyama, Koichi Sugamura, Taishi Nakamura, Yukio Fujiwara,
Eiichi Akiyama, Hirofumi Kurokawa, Toshimitsu Nozaki, Keisuke Ohba, Masaaki Konishi,
Hirofumi Maeda, Yasuhiro Izumiya, Koichi Kaikita, Hitoshi Sumida, Hideaki Jinnouchi,
Kunihiko Matsui, Shokei Kim-Mitsuyama, Motohiro Takeya, Hisao Ogawa
Des-fluoro-sitagliptin (DFS) is a dipeptidyl peptidase (DPP)-4 inhibitor which improves
glucose metabolism by increasing levels of active glucagon-like peptide (GLP)-1. Matsubara
and associates investigated the anti-atherogenic effects of DFS. DFS significantly improved
endothelial dysfunction and reduced atherosclerotic lesion area compared to placebo in
apolipoprotein E-deficient mice fed a high fat diet. In humans, the fasting plasma levels of
active GLP-1 were significantly lower in patients with coronary artery disease (CAD) than
those without CAD. The DPP4-inhibitor, DF-sitagliptin, exhibits strong anti-atherogenic
effects through augmenting GLP-1 activity in macrophages and endothelium and merits
further investigation in human models.
Editorial Comment: Toyoaki Murohara, p. 277EXPEDITED PUBLICATION EXPEDITED PUBLICATION280Lower Mortality in TAVI Patients With Lower Predicted Surgical RiskRuediger Lange, Sabine Bleiziffer, Domenico Mazzitelli, Yacine Elhmidi, Anke Opitz, Marcus Krane,
Marcus-Andre Deutsch, Hendrik Ruge, Gernot Brockmann, Bernhard Voss, Christian Schreiber,
Peter Tassani, Nicolo Piazza
Lange and colleagues reviewed data on over 400 patients at their institution who underwent
transcatheter aortic valve implantation (TAVI), and divided the subjects into quartiles based
on the time of their procedure. Patients in the first quartile had higher logistic EuroSCORES
and higher STS scores compared to patients in the most recent quartile. There was a
significant reduction in the crude 30-day and 6-month mortality rates from the earliest to the
most recent, but this difference was no longer significant after adjustment for baseline
characteristics. These results confirm that TAVI is now being offered to lower predicted
surgical risk patients and that outcomes of TAVI are better in lower surgical risk patients.
